Literature DB >> 9136840

Proton magnetic resonance spectroscopy of the brain in symptomatic and asymptomatic patients with liver cirrhosis.

J Laubenberger1, D Häussinger, S Bayer, H Gufler, J Hennig, M Langer.   

Abstract

BACKGROUND & AIMS: Hepatic encephalopathy (HE) is associated with typical changes of cerebral metabolite pattern observed by proton magnetic resonance (MR) spectroscopy consisting of a depletion of myo-inositol and an increase of glutamine. The aim of this study was to determine whether abnormalities in brain metabolism in neurologically asymptomatic patients with liver cirrhosis can be detected by spectroscopy.
METHODS: In a prospective study, 39 patients with liver cirrhosis were examined clinically according to standardized neuropsychological tests to define whether overt, subclinical, or no hepatic encephalopathy was present. All patients underwent proton MR spectroscopy at short echo times.
RESULTS: Spectroscopy allowed for the diagnosis of subclinical HE in 4 of 4 cases and of overt HE in 10 of 11 cases. In 24 cases of mere liver cirrhosis and normal neuropsychological testing, a typical metabolic pattern with a depletion of myo-inositol and an increased glutamine peak were found. A good correlation between the glutamine signal and the clinical grading was found.
CONCLUSIONS: Proton MR spectroscopy allows for the diagnosis of HE and subclinical HE, also shows the typical pathological metabolite pattern in patients with cirrhotic livers without subclinical HE, and might be more sensitive than neuropsychological testing. Glutamine could serve as a spectroscopic marker for the clinical state of the patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9136840     DOI: 10.1016/s0016-5085(97)70043-x

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  52 in total

Review 1.  Hepatic encephalopathy as a complication of liver disease.

Authors:  S vom Dahl; G Kircheis; D Häussinger
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

2.  Magnetization transfer ratio values and proton MR spectroscopy of normal-appearing cerebral white matter in patients with liver cirrhosis.

Authors:  A Rovira; E Grivé; S Pedraza; A Rovira; J Alonso
Journal:  AJNR Am J Neuroradiol       Date:  2001 Jun-Jul       Impact factor: 3.825

Review 3.  Clinical significance of basal ganglia alterations at brain MRI and 1H MRS in cirrhosis and role in the pathogenesis of hepatic encephalopathy.

Authors:  Laurent Spahr; Pierre R Burkhard; Hannelore Grötzsch; Antoine Hadengue
Journal:  Metab Brain Dis       Date:  2002-12       Impact factor: 3.584

Review 4.  Role of astrocytes in brain function and disease.

Authors:  Marta Sidoryk-Wegrzynowicz; Michal Wegrzynowicz; Eunsook Lee; Aaron B Bowman; Michael Aschner
Journal:  Toxicol Pathol       Date:  2010-11-12       Impact factor: 1.902

Review 5.  Proton magnetic resonance spectroscopy in portal-systemic encephalopathy.

Authors:  H Köstler
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

Review 6.  Neural synchronization in hepatic encephalopathy.

Authors:  Lars Timmermann; Markus Butz; Joachim Gross; Gerald Kircheis; Dieter Häussinger; Alfons Schnitzler
Journal:  Metab Brain Dis       Date:  2005-12       Impact factor: 3.584

7.  Cyclic GMP in blood and minimal hepatic encephalopathy: fine-tuning of the diagnosis.

Authors:  Jan Albrecht
Journal:  J Mol Med (Berl)       Date:  2007-02-02       Impact factor: 4.599

Review 8.  MR imaging findings in hepatic encephalopathy.

Authors:  A Rovira; J Alonso; J Córdoba
Journal:  AJNR Am J Neuroradiol       Date:  2008-06-26       Impact factor: 3.825

Review 9.  Magnetic resonance imaging and spectroscopy in hepatic encephalopathy.

Authors:  Laia Chavarria; Juan Cordoba
Journal:  J Clin Exp Hepatol       Date:  2013-11-07

Review 10.  Aquaporin-4 in hepatic encephalopathy.

Authors:  K V Rama Rao; M D Norenberg
Journal:  Metab Brain Dis       Date:  2007-12       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.